Incidence of and risk factors for major haemorrhage in patients treated with ibrutinib: An integrated analysis-Reference-Cited by-同舟云学术

Incidence of and risk factors for major haemorrhage in patients treated with ibrutinib: An integrated analysis

Published:2018-12-02 Issue:4 Volume:184 Page:558-569
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:Br J Haematol

Author:

Brown Jennifer R.¹^ORCID,Moslehi Javid²,Ewer Michael S.³,O'Brien Susan M.⁴,Ghia Paolo⁵,Cymbalista Florence⁶,Shanafelt Tait D.⁷,Fraser Graeme⁸,Rule Simon⁹^ORCID,Coutre Steven E.¹⁰,Dilhuydy Marie‐Sarah¹¹,Cramer Paula¹²,Jaeger Ulrich¹³,Dreyling Martin¹⁴,Byrd John C.¹⁵,Treon Steven¹⁶^ORCID,Liu Emily Y.¹⁷,Chang Stephen¹⁷,Bista Amulya¹⁷,Vempati Rama¹⁷,Boornazian Lisa¹⁷,Valentino Rudolph¹⁷,Reddy Vijay¹⁷,Mahler Michelle¹⁸,Yang Huiying¹⁷,Graef Thorsten¹⁷,Burger Jan A.³^ORCID

Affiliation:

1. Chronic Lymphocytic Leukemia Center Dana‐Farber Cancer Institute Boston MA USA

2. Vanderbilt‐Ingram Cancer Center Nashville TN USA

3. The University of Texas MD Anderson Cancer Center Houston TX USA

4. Chao Family Comprehensive Cancer Center University of California Irvine Orange CA USA

5. Strategic Research Program on CLL Università Vita‐Salute San Raffaele Milano and IRCCS Istituto Scientifico San Raffaele Milan Italy

6. Hôpital Avicenne Paris France

7. Mayo Clinic Rochester MN USA

8. Juravinski Cancer Centre McMaster University Hamilton ON Canada

9. Plymouth University Peninsula Schools of Medicine and Dentistry Plymouth UK

10. Stanford University School of Medicine Stanford CA USA

11. CHU Hopitaux de Bordeaux Pessac France